Drug Profile
Lu AF76432
Alternative Names: Lu-AF-76432Latest Information Update: 28 May 2021
Price :
$50
*
At a glance
- Originator Lundbeck A/S
- Class Neuroprotectants; Nootropics
- Mechanism of Action Type 1 cyclic nucleotide phosphodiesterase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cognition disorders
Most Recent Events
- 28 May 2021 No recent reports of development identified for phase-I development in Cognition-disorders(In volunteers) in United Kingdom (PO, Suspension)
- 22 Feb 2019 H. Lundbeck completes a phase I trial in Cognition disorders (In volunteers) in United Kingdom (PO) (NCT03531229)
- 17 Apr 2018 Phase-I clinical trials in Cognition disorders (In volunteers) in United Kingdom (PO) (NCT03531229)